<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Excitotoxicity and <z:mp ids='MP_0003674'>oxidative stress</z:mp> mediate neuronal <z:hpo ids='HP_0011420'>death</z:hpo> after <z:e sem="disease" ids="C0752304" disease_type="Disease or Syndrome" abbrv="">hypoxic-ischemic brain injury</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>We examined the possibility that targeting both <z:chebi fb="0" ids="31882">N-methyl-D-aspartate</z:chebi> (<z:chebi fb="0" ids="31882">NMDA</z:chebi>) receptor-mediated excitotoxicity and <z:mp ids='MP_0003674'>oxidative stress</z:mp> would result in enhanced neuroprotection against hypoxic-<z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>2-Hydroxy-5-(2,3,5,6-tetrafluoro-4-<z:chebi fb="0" ids="50127">trifluoromethyl</z:chebi>-benzylamino)-<z:chebi fb="0" ids="30746">benzoic acid</z:chebi> (Neu2000) was derived from aspirin and <z:chebi fb="3" ids="9334">sulfasalazine</z:chebi> to prevent both <z:chebi fb="0" ids="31882">NMDA</z:chebi> neurotoxicity and <z:mp ids='MP_0003674'>oxidative stress</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>In cortical cell cultures, Neu2000 was shown to be an uncompetitive <z:chebi fb="0" ids="31882">NMDA</z:chebi> receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi> and completely blocked free radical toxicity at doses as low as 0.3 micromol/L </plain></SENT>
<SENT sid="4" pm="."><plain>Neu2000 showed marked neuroprotection in a masked fashion using histology and behavioral testing in two <z:e sem="disease" ids="C1519106" disease_type="Experimental Model of Disease" abbrv="">rodent models</z:e> of focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> without causing neurotoxic side effects </plain></SENT>
<SENT sid="5" pm="."><plain>Neu2000 protected against the effects of middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp>, even when delivered 8 h after reperfusion </plain></SENT>
<SENT sid="6" pm="."><plain>Single bolus administration of the drug prevented gray and white matter degeneration and spared neurologic function for over 28 days after MACO </plain></SENT>
<SENT sid="7" pm="."><plain>Neu2000 may be a novel therapy for combating both <z:chebi fb="0" ids="31882">NMDA</z:chebi> receptor-mediated excitotoxicity and <z:mp ids='MP_0003674'>oxidative stress</z:mp>, the two major routes of neuronal <z:hpo ids='HP_0011420'>death</z:hpo> in <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, offering profound neuroprotection and an extended therapeutic window </plain></SENT>
</text></document>